Management of bone metastases in cancer: A review

被引：194
作者：
Selvaggi, G [1 ]
Scagliotti, GV [1 ]
机构：
[1] Univ Turin, Dept Clin & Biol Sci, S Luigi Gonzaga Thorac Oncol Unit, S Luigi Hosp, I-10043 Turin, Italy
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2005年 / 56卷 / 03期
关键词：
bisphosphonates; bone metastases; pain; hypercalcemia; radiopharmaceuticals; radiotherapy; PET; surgery; osteoclastic; osteolytic; pathologic fracture; skeletal-related event;
D O I：
10.1016/j.critrevonc.2005.03.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The presence of bone metastases is indicative of disseminated disease and typically indicates a short-term prognosis in cancer patients. Palliation of symptoms is the primary goal of therapy, with multidisciplinary efforts yielding the best results. New classes of drugs, such as bisphosphonates that significantly increase the time to first skeletal-related event (SRE), represent useful tools for the treatment of bone metastases. While the optimal duration of therapy needs to be defined, there is clinical benefit derived from the use of this class of agents. A potential role for bisphosphonates in the prevention of bone metastases is under current evaluation in clinical trials encompassing different solid tumor types. In combination with ongoing clinical trials, basic research to identify potential novel targets in the tumor cells-bone microenvironment will further define future strategies in the treatment of bone metastases. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：365 / 378
页数：14
相关论文
共 132 条
[1]  
ACHBAROU A, 1994, CANCER RES, V54, P2372
[2]  
Adams JE, 1983, BONE METASTASIS MONI, P107
[3]   DETECTION OF VERTEBRAL METASTASES - COMPARISON BETWEEN MR IMAGING AND BONE-SCINTIGRAPHY [J].
ALGRA, PR ;
BLOEM, JL ;
TISSING, H ;
FALKE, THM ;
ARNDT, JW ;
VERBOOM, LJ .
RADIOGRAPHICS, 1991, 11 (02) :219-232
[4]   Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases [J].
Bagan, JV ;
Murillo, J ;
Jimenez, Y ;
Poveda, R ;
Milian, MA ;
Sanchis, JM ;
Silvestre, FJ ;
Scully, C .
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2005, 34 (02) :120-123
[5]   Strontium-89 chloride in the treatment of bone metastases from breast cancer [J].
Baziotis, N ;
Yakoumakis, E ;
Zissimopoulos, A ;
Geronicola-Trapali, X ;
Malamitsi, J ;
Proukakis, C .
ONCOLOGY, 1998, 55 (05) :377-381
[6]   Recommendations for zoledronic acid treatment of patients with bone metastases [J].
Berenson, JR .
ONCOLOGIST, 2005, 10 (01) :52-62
[7]   Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, M ;
Blacklock, H ;
Bell, R ;
Simeone, JF ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :593-602
[8]   Profiling the safety and tolerability of bisphosphonates [J].
Body, JJ ;
Diel, I ;
Bell, R .
SEMINARS IN ONCOLOGY, 2004, 31 (05) :73-78
[9]   Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies [J].
Body, JJ ;
Diel, IJ ;
Lichinitzer, M ;
Lazarev, A ;
Pecherstorfer, M ;
Bell, R ;
Tripathy, D ;
Bergstronn, B .
BRITISH JOURNAL OF CANCER, 2004, 90 (06) :1133-1137
[10]   Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases [J].
Body, JJ ;
Diel, IJ ;
Lichinitser, MR ;
Kreuser, ED ;
Dornoff, W ;
Gorbunova, VA ;
Budde, M ;
Bergström, B .
ANNALS OF ONCOLOGY, 2003, 14 (09) :1399-1405
12345678910